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INTRODUCTION
The potential of systemic irradiation for the
treatment of disseminated malignant disease
was recognised almost immediately after the
discovery of radioactivity by Madame Curie in
1897. By 1905, a German physicist, Frederic
Dessauer, had designed an arrangement of x -
ray sources, which would give a homogenous
dose of radiation to the whole body. The
treatment of 3 patients with leukemia was
reported by Adalar Eifer in a Hungarian journal
in 1907. In 1923, Chaoul & Lange from the
University Clinic of Surgery in Munich treated 12
patients with Hodgkin's disease, of whom 8
showed responses which lasted at least 7
months (Chaoul and Lange, 1923).
Special equipment for total body irradiation
was installed at the Memorial Hospital, New
York, in May 1931 and by June of the next year,
Heublein reported results with 185 kV x - rays
given at a dose rate of 0.67 to 1.26 cGy per hour
to patients at a distance of 18-14 feet (5.5 - 7.5
metres). He concluded that the safe whole body
dose was 25% of an erythema dose (7.5 Gy
measured in air) and noticed "encouraging
improvement" in 3 out of 10 patients, but no
pronounced "beneficial clinical manifestations"
(Heublein, 1932). Nevertheless, this work
continued and, in 1942, an analysis of 270
patients was presented by Medinger and Craver
(Medinger and Craver, 1942).
Doses were limited to 3 Gy because of
haematological toxicity and research soon
started to find ways of overcoming this limitation.
Thomas et al. (Thomas et al.; 1957) reported
the use of intravenous infusion of bone marrow
to patients receiving radiation and
chemotherapy. The discovery of leuco -
agglutinating antibodies by Dausset (Dausset
and Nenna, 1952) stimulated much research
which led to the recognition of leukocyte
histocompatibility antigens. An understanding of
these was essential for the initial development
of safe bone marrow transplantation (BMT),
which removed the dose limiting toxicity of total
body irradiation (TBI) and permitted the use of
much higher doses. Increasing experience has
led to better ways to preventing graft versus
host disease (GvHD) and enabled rescue after
high dose therapy to be extended to the majority
of patients who do not have a fully compatible
sibling (Kernan et aI., 1993).
From the early 1970s, the pioneering work of
Donal Thomas, mostly in Seattle, has led to the
increasing use of total body irradiation as a
therapeutic method for many different
conditions. Initially patients with the most
radiosensitive tumours such as leukaemias and
lumphomas were treated (Thomas et al.; 1979),
but subsequently, systemic irradiation has been
tried with many other types of cancer and the
indications for treatment have been greatly
extended. Patients with haematological or
congenital metabolic diseases. where bone
marrow transplantation may correct the
underlying abnormality, have also been
irradiated, although preparation for
transplantation in these cases is more usually
given by chemotherapy alone.
A scientific basis for total body irradiation has
been difficult to establish because interacting
factors affect outcome of treatment. The effect
of high doses of 8 Gy or more to the whole body
on systems other than the bone marrow cannot
be studied unless fatality is prevented by bone
marrow transplantation or other stem cell
support. However, BMT produces problems, (of
which graft versus host disease is the most
severe), which may influence complications
such as interstitial pneumonitis in which
radiation plays an important part. It is also
difficult to determine how much radiotherapy
contributes to control of diseases in a multi-
modality treatment and it is unsatisfactory to
compare results between centres where many
aspects of patient management may differ.
However, over the last 10 years, our
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understanding of how to improve TBI schedules
has increased, particularly because of the
studies undertaken in the large number of
patients recorded by the International and
European Bone Marrow Transplant Registries
and through the continuing pioneering work of
the Seattle Group (Bortin et al.; 1992; Petersen
etal., 1992).
A AIMS OF TOTAL BODY IRRADIATION
At doses of 6 to 15 Gy, total body irradiation
will produce bone marrow ablation. For benign
disease, the intent of such treatments is to
provide enough immuno - suppression to allow
an infused marrow or stem cells to engraft
satisfactorily so that the underlying defect can
be corrected. For patients with diffuse
malignancies, the aim is to eradicate malignant
cells by high dose systemic radiotherapy (in
conjunction with chemotherapy) and to rescue
the patient from the inevitable bone marrow
toxicity by bone marrow transplantation or stem
cell infusion.
Thus, in the first situation, the therapeutic
agent is the transplant and in the second, it is
the high dose therapy which includes total body
irradiation. Obviously, the optimal scheduling of
total body irradiation Jor the two situations may
be different. Broadly speaking, chemotherapy
alone is often adequate to permit marrow
engraftment in patients with benign diseases,
although increased immune suppression
obtained by adding total body irradiation is
sometimes necessary after rejection of a first
graft or when HLA matching is less close. For
those with malignant disease however, the
search for ways of intensifying treatment
continues because in many situations relapse of
the initial disease remains the major problem,
and many regimens still include TBI as well as
high dose chemotherapy.
For each disease treated the following should
be defined:
1. The target cell population for the
treatment (that is part of the normal
immune system or a malignant cell
population).
2. The biological behaviour and radiation
response characteristics of the target
cell population.
3. The dose needed to achieve the
planned effect.
4. The most appropriate schedule of
irradiation.
5. The interaction of radiation with other
elements of the management of the
patients.
6. The complications likely to occur.
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A TYPES OF "RESCUE" AFTER HIGH DOSE
THERAPY
In the early days of high dose therapy, bone
marrow was used for "rescue" and could be
obtained from a number of sources. Identical
twin grafts (syngeneic bone marrow) offered
apparent advantages in being well tolerated by
the recipient. However, these grafts may be
associated with a higher rate of relapse because
of loss of a "graft versus leukaemia" effect which
offsets the advantage of a lower incidence of
transplant related complications.
Allogeneic grafts from a fully compatible family
member are usually preferred when available,
although these may cause graft versus host
disease. The scope of high dose therapy has
been widened by using partly compatible family
members or fully compatible unrelated donors,
although graft versus host disease and rejection
are major problems with these type of grafts. T
cell depletion of allogeneic "mismatched" or
unrelated grafts reduces graft versus host
disease, but leads to a higher incidence of graft
rejection and leukaemic relapse.
Reinfusion of autologous marrow (harvested
during remission) has been widely used. The
risk of persisting malignant cells being returned
to the body and leading to relapse may be
reduced by "purging" the marrow in-vitro to
remove tumour cells and has been reported to
improve outcome ina number of situations
(Brenner et aI., 1994). A major clinical problem
however remains the failure to eliminate all
tumour cells from the patient rather than from
the marrow for reinfusion. .
More recently, peripheral blood progenitor
cells (PBPC) have been harvested after
stimulation by appropriate colony stimUlation
factors. This procedure, which can be
undertaken on a out-patient basis, appears to
be satisfactory for ensuring engraftment. Early
results suggest that allogeneic peripheral blood
stem cells from a sibling donor may also be
used satisfactorily (Korbling et aI., 1995).
Manipulation of PBPC may be used to improve
outcome further, either by purging autologous
PBPC or by attempting to expand particular
progenitor cell populations in vitro before
reinfusion (Moolten, 1995). Though some
success has been reported, such manipulation
always leads to an increased risk of graft failure.
Another potential source of stem cells for
engraftment is cord blood.
A INDICATIONS FOR HIGH DOSE THERAPY
WITH TBI
B LEUKAEMIA
Most intensive treatments with haemopoietic
support are undertaken for leukaemia.
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C ACUTE LYMPHOCYTIC LEUKEMIA
Children with acute lymphocytic leukaemia at
high risk of relapse should be considered for
treatment in first complete remission. This group
includes those who fail to remit by day 28 of
standard therapy, those with biphenotypic
leukaemia or who have Ph+ cells, infants with
MLL gene rearrangement and those with high
hazard scores. Allogeneic matched related
donors should be used when available, but
allogeneic unrelated matched or related partially
mismatched grafts may be considered for those
at highest risk. Other children in the standard
risk group should be considered for
transplantation if they relapse after second
complete remission has been obtained. In this
group long - term survival may be expected in
50 - 70% of patients (Barrett et aI., 1994).
Relapse remains a major problem and attempts
to intensify preparation regimens have largely
resulted in increased toxicity without significant
improvement in survival rates.
In adults, results are less satisfactory because
of high relapse and complication rates, (four
year actuarial survival rates of 30 - 40%) and
BMT is reserved for those with Ph+ disease or
who are in second remission (Zhang et aI.,
1995).
C ACUTE NON LYMPHOCYTIC LEUKAEMIA
(ANLL OR AML)
Patients with acute myeloid leukaemia (AML)
may be transplanted in first remission if they
have a matched sibling donor. Relapsing
patients should be considered for autologous
bone marrow or PBPC, or unrelated matched
bone marrow support after high dose therapy in
second remission. Disease free survival rates ·of
50 - 80% at 5 years can be expected in a
selected young group of patients (Zittoun et aI.,
1995).
C CHRONIC MYELOID LEUKAEMIA
Allogeneic bone marrow transplantation after
high dose therapy is the only curative option for
patients with CML, although it is only feasible in
younger patients (aged < 55). Patients with
chronic phase disease are treated with
hydroxyurea, busulfan or interferon alpha to
obtain complete remission with disappearance
of Ph+ cells. Conditioning before bone marrow
transplantation is usually with cyclophospha-
mide/busulfan or cyclophosphamide and TBI. In
patients transplanted in chronic phase within 1
year of diagnosis, 5 year survival rates of
between 40 - 70% may be obtained. If· the
transplant is delayed to later in the chronic
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phase, the survival falls and in accelerated
phase disease, the survival after bone marrow
transplantation is less than 30%. This approach
is ineffective in patients who are treated in blast
crisis. Autologous transplantation is being
investigated and may prolong survival, although
elimination of Ph+ cells is unlikely. At the onset
of the disease, marrow purging may be possible
since there will be a residual population of
normal Ph- cells which declines as the disease
progresses. Attempts are being made to select
benign primitive progenitor cells from marrow
obtained early in the disease to use for marrow
reconstitution after conventional induction of
remission (Applebaum et aI., 1995).
B NON - HODGKIN'S LYMPHOMA
C HIGH GRADE
A large number of patients with lymphoma have
been treated with autologous bone marrow
transplantation at different stages of their disease.
A sub-set of patients with poor prognosis after
conventional therapy can be identified at
presentation and should be considered for high
dose therapy. This includes patients with
intermediate or high grade disease with poor
prognosis features (bone marrow or CNS
involvement and high LDH levels) who may be
considered for transplantation in first CR. Patients
in second remission, but whose disease remains
sensitive to chemotherapy may also be
transplanted with good results. This approach has
improved long term survival in this group from
20% to 50% overall (Philip et aI., 1995). Relapse
rates appear to be higher when autologous rather
than allogeneic support is used, but this
disadvantage is offset by the higher transplant
related morbidity seen with allogeneic
transplants. Allogeneic procedures may also offer
the advantage of a graft versus lymphoma effect
and relapse and progression rates are lower in
patients who develop chronic graft versus host
disease (GvHD). Because of the toxicity of this
approach, it is more suitable for young patients
«55) (Sweetenham et aI., 1994).
C LOW GRADE
Patients with short first or second remissions
from chemotherapy or those in whom only
partial remission can be obtained may have
improved survival after high dose therapy and
autografting (Rohatiner et aI., 1994). However,
this should not be the first approach because of
the risk of myelodysplasia after transplantation
and the long natural history of the disease.
There is no clear evidence of benefit from
purging the graft. Allogeneic transplantation may
improve control rates (Van Besien et al., 1995).
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B HODGKIN'S DISEASE
Patients with high risk or relapsed Hodgkin's
disease may also be appropriately treated by
high dose chemotherapy with or without TBI
(Nademanee et aI., 1995). Early transplantation
is recommended to avoid drug resistant disease
developing and to minimise cumulative toxicity.
B MULTIPLE MYELOMA
Young patients «55) with good initial
response to chemotherapy should be
considered for high dose therapy with PBPC or
autologous bone marrow, or allogeneic
transplant following high dose therapy with
melphalan alone or without TBL This approach
improves 5 year survival rates and, using
allogeneic marrow, a plateau in survival at
approximately 40% has been reported.
Regiments containing TBI appear to give better
results than those using chemotherapy alone.
This plateau in survival has not been seen in
patients treated with PBPC. Even in those
patients who relapse after high dose therapy
with TBI, survival after relapse may be
prolonged (Varterasian et aI., 1997).
B OTHER TUMOURS
C NEUROBLASTOMA
Only 12-20% of patients with stage 4 disease
will survive for more than 2 years after
conventional chemotherapy. Long term survival
rates of up to 40% may be obtained with intensive
initial therapy, appropriate local surgery or
radiotherapy, and early autologous or allogeneic
bone marrow transplantation after high dose
melphalan alone or with TBI.
Patients over the age of 1 or with n-myc
amplification should be considered (Stram et aI.,
1996). Purging of autologous marrow or PBPC
has been shown to reduce relapse rates. Current
studies are looking at ways of incorporating 1131
MIBG therapy, conventional chemotherapy and
high dose chemotherapy with TBI to improve
outcome in this group of patients.
Patients with disseminated Ewing's sarcoma,
PNET or rhabdomyosarcoma, where conventional
treatment has a low chance of producing cure, are
now being transplanted in well defined research
protocols.
Very selected young patients with breast
cancer may also benefit from high dose therapy.
Patients with high grade brain tumours are
being treated with high dose therapy, usually
with chemotherapy alone. In patients with solid
tumours such as these, radiotherapy is used for
local control rather than as part of the
conditioning for high dose therapy.
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A TECHNIQUES FOR TOTAL BODY
IRRADIATION
To obtain a large enough field to encompass
the whole body using a conventional treatment
unit, the machine must be used with an
extended source - patient distance as the
largest field size available at normal workin~
distances is usually of the order of 40 cm .
Under these working conditions, data obtained
for standard treatments cannot be used and
simple extrapolation is inaccurate. Depth dose
data must be obtained by direct measurement in
a finite phantom at an extended distance used.
The flatness of the beam at extended source -
patient distance must be determined. Scatter
contributed from walls, floor and treatment
couch must also directly measured and will be
different for each treatment room. Dose
distributions can be calculated from tissue air
ratios or computerized tomographic density
measurements. Special TBI planning systems
have been developed which incorporate
anatomical information from CT scanning with
parameters of dose calculation such as depth,
backscatter, tissue thickness, thickness of
inhomogeneity, off axis distance and source to
skin distance to give accurate predictions of
dose distribution (Van Dam et aI., 1988;
Sanches-Nieto et aI., 1997).
In vivo dosimetry can be performed with
thermoluminescent lithium fluoride monitors,
diodes or other in vivo dosimeters and only
these direct readings will fully take into account
variations in body dimensions at different levels,
differences between individual patients, the
effect of positioning of the body with regard to
the beam ahd the loss of internal scatter
because the fields is larger than the patient.
The maximum field sizes that can be obtained
depend on the size and the geometry of the
treatment room and are often unsatisfactorily
small, even when the patient is treated lying
along the diagonal of the beam to increase the
effective field size. Many centres will have no
choice of machine for total body irradiation and
will have to use either cobalt or linear
accelerator eqUipment chosen primarily by the
characteristics of the room in which it is situated.
The patient may need to be confined within the
available size by a device such as a specially
designed treatment chair or a perspex box of
the same dimensions as the field size (Barrett,
1982; Quast, 1987; Lutz et aI., 1988).
With the patient in the supine position and
treating with lateral fields, a more homogenous
dose distribution may be obtained using higher
energies of photons, such as 18 MV. If lung
shielding is used and the patient is treated with
AP/PA fields, 6 MV irradiation may give a more
Rep. Praet. Oneol. Radiother. 4 (3) 1999
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satisfactory distribution (Ekstrand et aI., 1997).
There is no clinical evidence of a difference in
outcome of treatment whether a cobalt machine
or linear accelerator at various energies is used
(Bortin et aI., 1982).
B HOMOGENEITY
By analogy with conventional radiation
treatment, it has been assumed that the aim of
total body irradiation should be to obtain as
homogenous a dose as possible to the whole
body. If open and unmodified beams are used,
inhomogeneities of up to 15% may be found. In
thinner regions of the body such as the neck
and ankles, doses may be larger than mid -
abdominal doses by up to 15%. Doses in the
lung are variable, but may be up to 10% higher
because of increased transmission in air. Doses
to the head may be low because they may be
within the penumbral region if the field size is
small or because of loss of internal scatter. The
patient's position also affects dose distribution.
For example, flexion of the neck to bring the
chin onto the chest will reduce doses to the
neck, and lung doses may be modified by
varying the position of the arms.
Many centres use compensators to decrease
doses to the lung or lower limbs or bolus around
neck or ankles to act as compensators. Lung
shields are used either as compensators to limit
the lung dose to that received elsewhere in the
body or to reduce the dose even lower to
minimise pulmonary complications of total body
irradiation. Some centres have considered
applying shielding of the kidneys or liver to limit
late toxicity (Miralbell et aI., 1996).
B BOOSTS
The assumption that homogeneity is desirable
may be questioned. The most effective
treatment may be one which delivers the highest
dose feasible to the areas most likely to contain
disease. In practice, this approach has been
used when boosts are given to various parts of
the body known to harbour residual disease or
to areas at high risk because of poor
chemotherapy access.
C TESTICULAR IRRADIATION
Prophylactic testicular irradiation after the
induction of remission in acute lymphatic
leukaemia is not considered beneficial. Although
isolated testicular relapse may occur, it is often
the herald of systemic relapse for which further
chemotherapy is indicated. However work from
North American centres such as Seattle and
Memorial Sloan Kettering Hospital have shown
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that the incidence of testicular relapse can be
reduced by giving an additional dose to the
testes before total body irradiation. This does
not influence the overall survival rate. Since
doses of 24 Gy are needed to prevent testicular
relapse after testicular involvement, attempts
have been made to boost testicular dose so that
when given in conjunction with total body
irradiation, doses are high enough to ensure
local control. Doses of 4 - 6 Gy fractionated
over 2 - 4 days are most commonly used. We
have recommended 3 doses of 1.8 Gy on
sequential days immediately prior to
cyclophospamide and total body irradiation.
C CENTRAL NERVOUS SYSTEM
Similar boosts have been used in some
centres to minimize the risk of CNS relapse.
There are insufficient data to establish whether
this approach is effective, although, as for the
testicular boosts, a dose of 1.8 Gy given on 3
successive days before total body irradiation
has proved safe and apparently effective in
minimizing CNS relapse.
C SPLENIC IRRADIATION
Patients with massive splenomegaly from
chronic myeloid leukaemia may be left with
residual splenic enlargement after
chemotherapy and additional radiation may be
given to the spleen. This -is best localised by
ultrasound and its position marked on the skin
immediately before treatment. Treatment should
be avoided if possible when platelet counts are
low and daily fractions sizes are usually of the
order of 0.5 to 1.5 Gy per day (Lapidot et aI.,
1988).
C NODAL AREAS
With the increasing use of high dose therapy
in the treatment of lymphomas, additional
treatment to initial or residual areas of nodal
disease may be considered advisable since
after bone marrow transplantation, most
lymphoma relapse occur in sites of previous
disease. Local radiotherapy may be given
before or after high dose chemotherapy or TBI.
Full therapeutic doses (35 Gy) have been
reasonably well tolerated after bone marrow
transplantation, although leukopenia and
mucositis may be troublesome (Abrams et aI.,
1997). It may be more convenient to plan to
deliver boosts to local nodal areas before TBI
using doses of 20 Gy to involved sites.
Particular care should be taken when irradiating
the mediastinum which may result in
pneumonitis (Rosalia et aI., 1996). If local
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treatment and TBI are given close to one
another, it is safest to restrict total cumulative
doses to 35 Gy.
8 SHIELDING
C LUNG SHIELDING
Lung shielding is used by approximately 80%
of European centres (Quast, 1987) undertaking
total body irradiation. Lead blocks are usually
made individually for each patient from suitable
planning films or from CT measurements to
cover the lung from the clavicle to the dome of
the diaphragm following the inner contour of the
chest wall. This arrangement shields only
approximately 60% of lung tissue and also
unavoidably 5% of bone marrow (Dutreix et aI.,
1986). Some techniques shield the lung for the
main part of the TBI treatment and then add a
boost to the bone - marrow - containing ribs
using electrons (Shank et aI., 1983). This is a
complex arrangement and additional lung dose
from the electron boosts are inevitable.
Scattered irradiation within the lung may also be
significant, but it is difficult to quantitate.
Shields are placed either close to the machine
head, which may make alignment with the
patient difficult, or in direct contact or very close
to the patient. Positioning may then be more
accurate, but may cause some discomfort to the
patient. It is difficult to ensure the accuracy of
shielding especially if treatments are prolonged
or if patients are restless or uncooperative; the
proximity of the mediastinum, liver and spleen,
to which full doses must be given, makes
accuracy very important. However, from the
work of Dutreix it can be seen that shielding is
only effective for at most 60% of the lung
volume; 30% lies within the mediastinal fields
and 5% in the apex where shielding is difficult,
although lung doses may be highest. For this
reason and because of concerns about
accuracy in placing shields, some centres prefer
to use no lung shielding, but to restrict doses to
those known to be within tolerance.
A reduction in the incidence of interstitial
pneumonitis when shielding was introduced has
been claimed by many groups, but often this
change coincided with a reduction in effective
whole body doses by fractionation or more
careful measurement of lung doses. It is not
clear whether the development of interstitial
pneumonitis can be provoked by high doses to
part of the lung only or whether partial protection
is effective. The role of lung shielding, except to
provide compensation if homogeneity of
treatment is being sought, therefore remains
unclear. Similar rates of interstitial pneumonitis
are reported by groups using techniques with
and without lung shielding (Bortin et aI., 1982).
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8 SPECIFIC TECHNIQUES
Most groups giving total body irradiation
treatments use a standard cobalt unit or linear
accelerator (4 - 18 MV) operating at a source
skin distance (SSD) of approximately 4 metres
which will usually give field sizes from 128 - 160
em. Within this field size, patients may lie
supine, on their side or be seated with knees
bent up on a special chair.
Perspex of up to 2 cm in thickness is usually
placed next to the patient, both on the beam
side (entry) to prevent skin sparing, which would
occur with high energy irradiation and is
undesirable because leukaemic cells may
infiltrate the skin, and on the exit side to absorb
backscatter from walls which increases skin
dose without adding usefully to mid plane doses
(Van Dam et aI., 1988).
Special total body irradiation units have been
installed in a number of centres. In Toronto, a
single source wide angled collimator unit
permits large field irradiation at a short
treatment distance. Dual source treatment
facilities have been available for many years in
Seattle, where 2 opposing cobalt sources are
mounted on floor rails to allow adjustment of
treatment distances as sources decay (Thomas
et aI., 1979). The patient is placed between the
2 horizontal beams. At the Royal Marsden
Hospital (RMH) in London dual cobalt sources
are mounted vertically and provide field sizes of
2 x 0.65 m at 2 m SSD; in Boston,
Massachusetts, two 4 MV linear accelerators
similarly mounted give field sizes of 80 x 220
cm2 , These special facilities provide tfle
possibility for varying the parameters of
treatment which are fixed with most single
source units because of field size constraints
(Lutz et aI., 1988; Lewis and Rosenbloom,
1988).
Where there is no room large enough for total
body irradiation, some centres have used a
scanning cobalt beam, to cover the whole body.
This has the theoretical disadvantage that not all
the malignant cell population is being irradiated
at the same time and that the incident dose rate
is higher than when whole body treatment is
given at extended distances. In practice, there is
little evidence to suggest that this technique is
less effective, although a higher incidence of
interstitial pneumonitis has been reported with a
sweeping beam technique than with a static
beam (Kim et al., 1985).
Most patient are treated with postero-anterior
and antero-posterior fields because the
increased thickness of the body when lateral
fields are used leads to less satisfactory dose
distributions. This effect is less obvious in
children. High energy accelerators (>18 MV)
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may give a better dose distribution if lateral
fields are used to treat the supine patient. If
vertical treatment units are used with the patient
supine, it is possible to place lung shielding
more accurately. With the patient lying on his
side, careful positioning of the arms may
contribute to compensation for increased lung
transmission.
Some centres in the United States and Europe
have adopted the technique first developed at
the Memorial Hospital in New York where
patients are treated standing supported by a
modified bicycle seat and arm supports, with
lung shields suspended from their shoulders.
Additional boost treatments are then given with
electrons to the chest wall to increase the dose
to bone marrow bearing ribs (Shank et aI.,
1983).
From analysis of treatment results notified to
the International and European Bone Marrow
Transplant Registries, there is no evidence for
superiority of one treatment technique over
another and factors such as the dose given and
the sCheduling of total body irradiation are likely
to be much more important (Bortin et aI., 1982).
B TOTAL LYMPHOID IRRADIATION
Total lymphoid irradiation (TLI) was proposed
by Slavin et aI. (Slavin et aI., 1983) as a way of
producing immuno - supression without the lung
toxicity of total body irradiation. It permitted
stable chimerism after bone marrow
transplantation and was widely used to facilitate
organ engraftment. Initially, beneficial
symptomatic response in auto-immune diseases
such as systemic lupus erthymatosis and
rheumatoid arthritis was reported (Strober et aI.,
1985), but these responses may not be long-
lasting and a relatively high incidence of
secondary B - cell malignancy has indicated
that this approach should be used with caution.
TLI has been used for conditioning patients with
aplastic anaemia after graft rejection, but it is a
complicated technique and appears to offer little
advantage over low dose total body or thoraco -
abdominal irradiation. With TLI, doses of 20 -
34 Gy with conventional daily fractionation have
been used. It has also been used in some
centres before or after total body irradiation to
produce additional immune suppression for
patients receiving T-cell depleted marrow
grafts.
Shaped fields such as mantle and inverted Y
(used more commonly in the treatment of
Hodgkin's disease) or thoraco - abdominal
fields with lung shielding may be used to deliver
doses of 5 - 6 Gy.
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A SCHEDUUNG OF TOTAL BODY
IRRADIATION
In conventional radiotherapy, regimens can
only be considered isoeffective if they produce
the same degree of tumour control for the same
level of toxicity to normal tissue. In practice, the
acute tolerance of normal tissues is likely to limit
the doses that can be given, although late
damage may be more critical. For total body
irradiation, three endpoints must be considered
if regimens are to be compared.
1. Effect on cells of the immune
system.
2. Control of leukaemic or other
tumour cell population.
3. Effect on normal tissues other than
bone marrow (whose function can
be effectively replaced by the
transplant procedure).
After bone marrow, the next most sensitive
organ to damage from total body irradiation is
the lung, with liver and kidney also at risk from
similar or higher doses. For proper comparison
of one schedule with another the question must
be asked, do these two regimens produce equal
rates of engraftment, control of initial disease
and incidence of interstitial pneumonitis (and
other normal tissue toxicity)? One treatment can
only be proved to be better than another if it can
be shown that, for equal rates of normal tissue
toxicity, tumour control or engraftment
(whichever is the most significant clinical factor)
is improved. Unfortunately not all studies are
constructed in this way and it may be difficult to
conclude that a particular schedule is better
than another if only one of the parameters is
reported.
Analysis of treatment results is further
complicated by the timescales of the different
endpoints. Failure of engraftment will be obvious
within 2 to 3 weeks and interstitial pneumonitis
occurs most commonly up to 100 days after
total body irradiation. Leukaemic or other
tumour cell relapse however may occur at any
time up to several years after treatment.
Because patients who have died early with
interstitial pneumonitis will be lost to the total
analysis of tumour relapse, its true incidence
with that schedule will be impossible to
determine. Because of these problems, rates of
interstitial pneumonitis have commonly been
used as the single endpoint for comparison of
schedules of total body irradiation.
However, using data from large reported
series of TBI treatment and derived alpha bete
ratios for each of the normal tissues and the
tumour population at risk (in so far as these can
be determined from the literature) it should
theoretically be possible to calculate an optimal
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schedule for TBI. In practice, because tumour
cell populations and normal tissues vary in
radiosensitivity both within patients and in
different organs as well as between patients, it
may not be possible to demonstrate a single
"best treatment". Most of the currently used
schedules have been shown empirically to be
reasonably well tolerated. Differences in tumour
cell population control are difficult to
demonstrate since quantitation of residual
disease after induction chemotherapy has not
been possible up till now and there may be
considerable variation in total tumour cell
numbers in different patients who are apparently
in complete clinical remission. Quantitative PCR
of bone marrow may help to elucidate this
situation.
B RADIOSENSITIVITY OF CELLS OF THE
NORMAL HAEMOPOIETIC AND IMMUNE
SYSTEMS
Early work by Till and McCulloch (Till and
McCulloch, 1962) using the exogenous spleen
colony assay system in mice showed that bone
marrow stem cells have a limited capacity to
repair sub - lethal damage. Similar radiation
survival curves have been obtained with human
bone marrow cells cultured in -vitro (Senn and
McCulloch, 1970). Because of these typical cell
survival curves, little effect is expected from
changes in radiation schedule and this has been
confirmed in a number of experimental systems.
However, Tarbell et al. (Tarbell et aI., 1989)
have shown Do values of 80 cGy for single
fraction high dose rate treatment, 85 cGy for low
dose rate single fractions and 55 - 65 cGy for
fractionated regimens, suggesting increased
sensitivity to fractionated treatment.
Nevertheless, overall it seems reasonable to
conclude that the effect of variations in dose
rate and fractionation are insignificant for the
killing of normal bone marrow cells which
represent a very radiosensitive population.
The LDso for man from bone marrow ablation
is 4 Gy and in patients with nonmalignant
disease undergoing bone marrow
transplantation, doses of 6 Gy appear
necessary to ablate host marrow adequately to
allow engraftment of donor marrow. This is
below the Jevel at which lung damage will occur
and scheduling therefore is not critical if killing
normal stem cells is the only consideration.
The complication of graft versus host disease
after bone marrow transplantation can be
greatly reduced by the in-vitro manipulation of
harvested bone marrow to reduce T cell
numbers. The use of T cell depleted bone
marrow however results in a markedly increased
rate of graft rejection as well as of leukaemic
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relapse. The mechanism for the failure of
engraftment after T cell depletion is not clear,
although host natural killer cells and T
lymphocytes have been implicated. Empirical
intensification of conditioning for bone marrow
transplantation with T cell depleted marrow has
resulted in increased rates of graft versus host
disease. There are differences in radiosensitivity
in-vitro for the various lymphocyte subsets (T, B,
OKT4 , OKTa) which may be responsible for
these outcomes (Uckun et aI., 1992). Further
studies are needed to determine which cell is
responsible for graft rejection and to elucidate
the role of increased doses of total body
irradiation in the abrogation of graft failure.
B RADIOSENSITIVITY OF LEUKAEMIC AND
OTHER MALIGNANT CELLS
O'Donoghue in his review of the literature of
the in-vitro radiosensitivity of human leukaemic
cell lines has found descriptions of 8 different
lines (including 3 lymphomas) and
measurements of bone marrow or peripheral
blood leukaemic progenitor cells from 20
patients (O'Donoghue, 1986). These studies
confirmed that leukaemic cells are highly
radiosensitive with a low capacity for the
accumulation and repair of sub-lethal damage.
As for normal stem cells, little effect of changes
in dose rate or fractionation would therefore be
expected. However for this cell population, the
doubling time must also be considered. This
would be likely to be insignificant for continuous
low dose radiation, but if a doubling time of 2.5
days is considered, fractionation over a period
of 5 days could result in a reduction in log cell
kill of 0.6. Direct studies of the effects of various
schedules of total body irradiation on leukaemic
cell in-vitro have been reported. There is some
evidence of increased survival of leukaemic
cells in-vitro when radiation is given as a split
course compared with continuous radiation to
the same total dose.
For control of leukaemia and other
malignancy, it can be assumed from general
experience in radiotherapy that increasing dose
of radiation will produce increased tumour cell
kill. This can be shown using the same
technique and scheduling of total body
irradiation, by demonstrating reduction in rates
of relapse as the dose is escalated and has
been confirmed by studies from various groups.
In a study of escalating single fraction low dose
rate total body irradiation in 238 patients at the
Royal Marsden Hospital, London, a lower
relapse rate was noted after 10.5 Gy than 9.5
Gy although at a higher dose of 11.5 Gy any
benefit in preventing leukaemic relapse was
offset by a high early death rate from lung
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damage. Similarly the Seattle group have shown
a lower rate of leukaemic relapse with 15.7 Gy
compared with 12 Gy, although at the expense
of a higher transplant related mortality (Petersen
et aI., 1992). However, for other tumour types
whose radiobiological characteristics will be
different, dose should not be considered in
isolation (Peters et aI., 1979).
In addition, other biological factors such as
total body burden of tumour may outweigh an
possible advantage of increasing dose within
the range feasible because of normal tissue
damage.
B NORMAL TISSUES
A direct effect of increasing the total irradiation
dose on the incidence of damage to normal
tissue can also be demonstrated. For the lung,
the dose limiting tissue in total body irradiation,
the response curve using upper half body
irradiation for disseminated malignant disease
shows an apparent threshold below which lung
damage is not clinically apparent, with a very
steep increase in incidence with dose over the
range 9 -10 Gy (Keane et aI., 1981). For single
fraction low dose treatments in the RMH
experience, the incidence of interstitial
pneumonitis rose from 30% with 10.5 Gy to 69%
with 11.5 Gy. Similar steep responses have
been with high dose total body irradiation in the
range of 7 - 8 Gy. Work from Seattle suggests
that when fractionated total body irradiation with
2 Gy fractions is used, maximum tolerated lung
doses are of the order 14 -15 Gy.
Isoeffective schedules of total body irradiation
for the endpoint of clinical lung damage
manifested as interstitial pneumonitis are
reasonably well established as 7.5 Gy single
fraction high dose rate, 10.5 Gy single low dose
rate and 14 - 15 Gy with fractionated TBI.
Several experiments and clinical studies have
now suggested that although considerable
sparing of normal tissue damage may be
achieved in single fraction treatments by
lowering the dose rate, regimens using small
dose fractions are likely to be best, since for
equivalent toxicity, dose rate for a single fraction
would have to be very low leading to very
prolonged treatment times which are not
feasible in practice. Fractionated TBI is
therefore now widely used, although there is
great variation in the dose per fraction.
The response of the lung to fractionated
radiotherapy is dependent much more on
fraction size than duration of treatment. The half
time for repair of lung is estimated to be
approximately 1.5 h hours and a minimum of 6
hours is needed between fractions to ensure
that repair is complete. Many groups report a
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reduced incidence of pneumonitis with
fractionated total body irradiation but in many
cases all that has been accomplished effectively
is a reduction in overall dose. If fractionated
radiotherapy is to be used, it is likely that the
most benefit will be obtained using relatively
small doses per fraction «2 Gy) although even
lower fraction sizes (1.2 Gy) may be beneficial
in terms of lung sparing and clinically feasible
and effective (Shank et aI., 1983). Within the
range of dose used per fraction, little additional
benefit is gained using low dose rate as
opposed to the standard output of most
machines, although additional sparing with very
low dose rates has been reported
experimentally. Similar dose response curves
and a beneficial effect of fractionation in
reducing late damage have also been
demonstrated for liver, kidney and lens.
In summary therefore, toxicity to normal
tissue, efficacy against tumour population and
feasibility in term of delivery must be
considered, as well as overall treatment time
and time between fractions. Regimens such as
those from Seattle, UK MRC and US Memorial
Sloan Kettering regimens all offer the advantage
of high dose, low dose per fraction and
reasonable overall treatment time and therefore
appear to be the most satisfactory at present.
Clinical trials from Seattle have recommended a
total dose of 14.4 Gy in children and 13.2 Gy in
adults and this corresponds very well with the
UK experience with the MRC protocol of 14.4
Gy (maximum lung dose in 8 fractions of 1.8 Gy
given over 4 days) (Demirer et aI., 1995).
Further experience with treating patients with
other tumours may lead to a change in these
recommendations, but this is unlikely since the
parameters of normal tissue toxicity will not vary.
A DRUG-RADIATION INTERACTIONS
As total body irradiation is only one element of
the conditioning regiment, drug-radiation
interactions must be considered in assessing
the effectiveness or tOXicity of a particular
treatment. For many years, the combination
developed by the Seattle Group of
cyclophosphamide 120 mg/kg given on days 4
and 3 before total body irradiation has been
widely used (Thomas et aI., 1979). The
continuing problem of leukaemic relapse after
bone marrow transplantation has led to attempts
to intensify conditioning before grafting in
various ways. Radiation dose and fractionation
may be modified (Petersen et aI., 1992), or more
commonly alternative drugs or several
chemotherapeutic agents have been used in
combination. Unfortunately most of these
studies have either found no improvement in
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relapse rates or have found that an
improvement in relapse rate is offset by an
increase in transplant related morbidity and
mortality (Ringden et aI., 1983; Gorgon et aI.,
1997; Kumar et aI., 1997; Hjiyiannakis et aI.,
1997).
Attempts to replace total body irradiation with
drugs have been made and the most widely
used chedule is that developed by Santos of
cyclophosphamide (60 mg/kg x 2) and busulfan
(4 mg/kg x 4) (Santos et aL, 1983). Results
comparable with those from total body
irradiation containing regiments are obtained.
Both total body irradiation and busulphan are
potent stem cell killers. The spectrum of
morbidity is defferent and the optimum schedule
must be determined taking these factors into
consideration (Ringden et aI., 1994).
For the radiation oncologist directing TBI
treatments, one of the persisting challenges is to
assist in developing more effective, but less
toxic preparatory regiments. In many cases, the
effects of individual drugs given in conjuction
with radiation are well known, and potentially
toxic drugs such as cytosine arabinoside,
methotrexate and cisplatin can be avoided. As
new drugs are developed and added to
conditioning regimens, constant vigilance and
careful observation' are needed to detect any
unforeseen interactions.
A COMPLICATIONS OF TOTAL BODY
IRRADIATION
B ACUTE EFFECTS
Nausea and/or vomiting may be expected in
most, but not all, patients after total body
irradiation. After single fraction exposures at low
dose rate, vomiting occurred in 75% of patients
after a dose of 2- 3 Gy had been received
(Westbrook et aL, 1987). When fractionated
total body irradiation is used, vomiting may be
less marked, but occurs in most patients
between 1Y2 - 8 hours after the start of the
treatment. It is difficult to separate the emetic
effects of chemotherapy and radiotherapy in this
situation when chemotherapy is given before
TBI. Data from patients treated with
cyclophosphamide after TBI suggest that this
drug does play a major role in the nausea!
/vomiting that is seen with high dose therapy.
Nausea and vomiting may continue up to 4 days
after irradiation and may be associated with
diarrhoea related to direct toxicity on the gut.
Children under 10 years of age may experience
less vomiting than adults. Vomiting may be
precipitated by movement and general
discomfort and reduced by fasting and anti-
emetics. The most effective anti - emetic
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prophylaxis appears to be with a combination of
a 5 hydroxy triptamine (5HT) antagonist such as
ondansetron with dexamethasone (Spitzer et aI.,
1994).
Acute damage to the gut may be reflected by
severe diarrhoea, anorexia, and cramping
abdominal pain occurring within 4 or 5 days of
irradiation. Histologically, there is evidence of
flattening of crypt epithelium and degeneration
of crypt cells by 10 days after treatment. Repair
occurs usually within 20 days. Damage to the
villi may result in malabsorption, although
complete recovery normally occurs.
Total body irradiation may also cause
hypotension and pyrexia which may be
worsened by the use of drugs such as
chlorpromazine and ameliorated with steroids.
Bilateral parotitis is common after total body
irradiation, but usually resolves within 24 hours.
It is associated with a rise in the parotid iso-
enzyme serum amylase with no change noted in
pancreatic amylase (Barrett et aI., 1982). Values
return to normal by 6 days and there are
normally no sequelae although xerostomia may
persist for up to a year after the treatment.
Pilocarpine may help to stimulate saliva flow
after treatment. Careful attention to dental
hygiene is necessary if the mouth remains dry to
prevent further complications. Graft versus host
disease will exacerbate the oral sequelae of
treatment (Dahllof et aI., 1997).
In treatments uncomplicated by graft versus
host disease or drug tOXicity, no immediate
changes in serum urea, electrolytes, liver
function tests, calcium, phosphate or alkaline
phosphatase have been noted. There is a rapid
fall in the lymphocyte count to 50% by the end of
treatment with single fraction total body
irradiation with a half time of 30 hours, and to
60% 13 hours after the first fraction of a
fractionated course. Rises in granulocyte
concentrations may be very marked (200 -
400% of initial value) after only 10 minutes of
total body irradiation, although numbers then
decline rapidly to initial or lower values. No
changes in platelets or red cell numbers were
noted up to 72 hours after the start of total body
irradiation (Girinsky et aL, 1991). Increased
levels of adrenaline and especially
noradrenaline may be seen after total body
irradiation. No short term changes in
concentrations of Ts or T4 are noted, although
TSH values are lowered after 10 Gy in most
cases.
Reversible alopecia would be expected from
the dose levels used for total body irradiation.
This factor cannot be separated from the effects
of chemotherapy and permanent impairment of
hair regrowth may occur. Changes in colour or
texture of regrowing hair are common.
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B LATE EFFECTS
In radiobiological terms, effects on lung, liver
and kidney may be termed late, although in
practice, damage to these organs from total
body irradiation may manifest itself within 1 to 6
weeks of irradiation.
CLUNG
Interstitial pneumonitis and graft versus host
disease are the two most important factors
contributing to early death after bone marrow
transplantation. Interstitial pneumonitis is
characterized by fever, dyspnoea, cough and
hypoxia within the period up to 100 days after
transplantation. Chest radiographs show
characteristic bilateral changes of diffuse
interstitial infiltrates, and lung function testing
shows a reduction in diffusing capacity.
Histological changes of oedema, cellular
infiltrates, alveolar exudation, type 2
pneumocyte proliferation and later collagen
deposition are seen.
The clinical syndrome of pneumonitis is due to
an accumulation of activated T cells in the lung
with an associated population of macrophages
and neutrophils (Nakayama et aI., 1996). There
is an increase in cells expressing messenger
RNA for inflammatory proteins such as tumour
necrosis factor alpha, interleukin 1 beta, and
transforming growth factor beta (TFG beta). The
host MLC class II expressing cells are increased
in lung after lBI and this process is potentiated
in patients undergoing allogeneic transplant or
those with lesser degree of matching whereas it
is rare with syngeneic transplants or autologous
grafts. These acute changes lead to a process
of type 2 pneumocyte proliferation and collagen
deposition with fibrosis.
In many cases, specific aetiological factors
may be detected. Up to 40% of cases are
associated with cytomegalovirus or other
infection. Cytomegalovirus infection can be
diagnosed by culture of lung tissue, by bronchial
alveolar lavage or by identifying the
characteristic viral inclusion bodies in lung
biopsies. The mortality from this condition is
high. Other possible infective agents are
pneumocystis, (which may largely be prevented
by prophylactic administration of trimethoprin-
sulpha methoxasole), herpes simplex or zoster,
aspergillus, candida and other fungi and a
variety of bacteria. In approximately 60% of
patients with interstitial pneumonitis, no
infectious agent can be detected and a
diagnosis of idiopathic pneumonitis is made.
The risk of interstitial pneumonitis is increased
by the use of methotrexate rather than
cyclosporin for immunosuppression after
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grafting, older age, presence of severe graft
versus host disease, long interval from
diagnosis to transplantation, poor performance
status pre-transplant and high dose rate total
body irradiation (Pino et aI., 1982). In the IBMTR
series, for patients with none of these factors,
the probability of developing interstitial
pneumonitis was 8% compared with 94% in
patients with all these factors. There was no
evidence from this study of an advantage for
fractionated radiation in reducing pneumonitis
and no dose response relationship was detected
for radiation doses to lung between 5.6 and 12.8
Gy (Bortin et aI., 1982).
Methotrexate appears to have more direct
toxicity for lung than cyclosporin. This may be
because of a potentiating effect of radiation
damage. The cyclosporin syndrome of adult
respiratory distress (ARDS) may be seen after
renal toxicity has developed from high dose
treatment. Increasing age may increase risk of
pneumonitis because there is a greater
likelihood of prior infection with cytomegalovirus.
Graft versus host disease also increases the
risk of pneumonitis by immunological and
infective processes.
The lack of correlation in the study above of
pneumonitis with total dose contrasts strongly
with data presented by Keane et al. (Keane et
aI., 1981) who showed a clear dose response
relation over the range of 7-100 Gy. This may
have been obscured in the data from the
International Bone Marrow -Transplant Registry
by different ways of reporting doses or by the
fact that some of the schedules were delivering
doses below the threshold for lung damage.
CLIVER
Liver damage in recipients of bone marrow
transplants may be related to the conditioning
regiment, to graft versus host disease or to
infection either previously or neWly acquired.
The clinical picture of radiation or chemotherapy
associated liver damage develops within a few
weeks of treatment with weight gain, jaundice,
abdominal pain, hepatomegaly, ascites and, in
severe cases, encephalopathy. This condition is
associated with a high mortality rate and is more
often seen after preparation of patients with
busulfan than with TBI.
Histopathological changes are of veno-
occlusive disease, where the terminal hepatic
venules and sub-lobular veins are narrowed by
sub-endothelial fibrosis and thickening with
trapping of cells, including hepatocytes, within
the lumen resulting in obstruction to sinusoidal
blood flow. Although factors other than radiation
are usually more important in its causation, the
incidence is reported to be lower after
57
Barrett: Total body irradiation.
fractionated than high dose-rate single fraction
TBI. Low dose heparin and tissue plasminogen
activators such as alteplase have been used to
try to reduce the severity of this problem.
Spontaneous resolution within 3 to 4 weeks may
occur (Baglin, 1994).
C KIDNEY
There are many factors which may contribute to
renal damage during the preparation for and
recovery from bone marrow transplantation
including the use of chemotherapeutic agents
such as ifosfamide, antibiotics and cyclosporin.
Tests of glomerular function after bone marrow
transplant f TBI usually show only minor
impairment. Tubular defects and haemolytic
uremic syndrome are more likely to occur, but are
more related to drugs than radiation exposure
(Patzer et aI., 1997). Endothelial injury is
characteristic of acute radiation nethropathy
which is related to dose of radiation. The doses
used for TBI should be below the threshold for
overt damage. Although renal failure is a common
problem of multi-factorial aetiology after bone
marrow transplantation, it is difficult to quantitate
precisely the contribution of TBI. Mirabell
however has shown a dose dependent effect in
his patients (Mirabell-et aI., 1996).
Radiation nephritis is a well recognized entity
after local field irradiation to doses in excess of 20
Gy and may occur many years after exposure.
The first report of radiation nephritis after total
body irradiation was by Bergstein et aL (Bergstein
et aL, 1986). Two children developed
hypertension, haematuria and impaired renal
function 6 months after treatment. Histologically
the kidney showed expanded mesangial zones,
thickening of capillary and arteriolar walls, focal
areas of tubular atrophy and interstitial oedema
and fibrosis. One of the patients had received
cyclosporin and acyclovir, drugs with known renal
toxicity. Tarbell et aL (Tarbell et al., 1988) found
evidence of renal dysfunction in 11 out of 29
survivors of transplantation for acute
lymphoblastic leukaemia or neuroblastoma
between 1980 and 1986. Conditioning regimens
had included drugs with renal toxicity such as
cisplatin teniposide and ifosfamide. Patients
presented with anaemia, haematuria and a rising
creatinine: biopsy in 2 patients showed changes
consistent with radiation nephritis or the
haemolytic uremic syndrome.
It thus appears that the tolerance of the
kidney to radiation may be diminished when
multi agent chemotherapy is used
concomitantly and children may be especially
susceptible. Because of the late onset of
radiation nephritis, this problem may increase
in severity with longer follow - up of survivors
of bone marrow transplantation.
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CEYE
Marked changes are observed in transplanted
patients who develop chronic graft versus host
disease with kerato-conjunctivitis and changes
in lacrimal gland secretions. Retinitis may result
from conditioning with cytosine arabinoside and
TBL In uncomplicated survival after total body
irradiation, the only change to be observed is
the development of cataract. In the Seattle
series reported in 1984 (Deeg et aL, 1984), the
risk of developing cataract was 18% and 19% in
patients treated with chemotherapy or
fractionated total body irradiation and 80% in
those receiving single fraction total body
irradiation. All cases were bilateral and the risk
increased for 3 years after transplantation
before stabilizing. Surgical excision was
necessary in half the patients. Chronic graft
versus host disease and steroid therapy were
also associated with a higher risk of developing
cataracts. With low dose single fraction total
body irradiation, the incidence is lower than after
high dose single fraction treatment, but higher
than with fractionated irradiation being of the
order of 58% at 10 years (Fife et aI., 1994).
CTEETH
Disturbances in tooth development and size
are seen after BMT with TBI with a severity
inversely proportional to age at the time of
treatment (Nasman et aL, 1997).
C CENTRAL NERVOUS SYSTEM DAMAGE·
A syndrome of somnolence with lassitude,
anorexia and sometimes vomiting, may be
expected at about six weeks after TBI. A similar
picture is seen after cranial irradiation for ALL
and is believed to be due to transient
demyelination. No treatment is needed as the
condition improves spontaneously (within seven
to ten days). It does not correlate with any
persisting or late damage.
Leukoencephalopathy may occur within days
or months of transplantation and may be related
to drug administration (especially high dose
methotrexate), radiation or viral infection. It is
uncommon after total body irradiation unless
previous cranial irradiation has been given and
the incidence is inversely correlated with age.
The characteristic appearance on computerised
tomographic scanning is of dilated ventricles,
cerebral atrophy, hypodense areas and
calcification.
Damage to the spinal cord has been reported
anecdotally but is rare.
By extrapolation from results of prophylactic
cranial irradiation for leukaemia, impairment of
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cognitive function and learning ability would be
expected, although there are few detailed long
term studies yet (Peper et aI., 1993).
C QUALITY OF LIFE
Quality of life after bone marrow
transplantation may be impaired. In a study from
Toronto, many patients reported low grade
symptoms such as fatigue, pain, joint stiffness
and sleep disturbance. Patients studied at less
than 3 years from the time of transplant
experienced considerable impairment, while
longer term survivors were indistinguishable
from the normal population in most areas
studied. However, 81 % of patients were
prepared to recommend a transplant for
somebody in similar circumstances (Sutherland
et aI., 1997).
C HORMONAL CHANGES
D GONADAL FUNCTION
Gonadal function and fertility are known to be
affected by high dose chemotherapy and total
body irradiation. The degree of impaired
function depends on age, sex and dose and
type of therapeutic agent used.
In adult women, the usual pattern seen after
T81 is ovarian failure with amenorrhea, low
plasma oestradiol levels with raised
gonadotrophins, and infertility. Low androgen
levels may be found, probably also resulting
from ovarian damage. A direct effect on the
adrenal gland may occur although no
abnormalities of plasma cortisol levels have
been reported. Since androgen is needed to
sustain increased muscle activity during
exercise, low levels may help to explain the
easy fatiguability reported by patients after T81
(Hovi et aI., 1997).
In very young but post - pubertal females,
ovarian recovery may be seen in 10 - 25% at 2
- 7 years after 8MT. Recovery is not affected by
hormone replacement therapy and this may be
temporarily discontinued to assess whether
recovery has occurred. It is possible that this
group of patients may undergo early
menopause (as has been reported after
chemotherapy).
In men, the most common pattern is of
infertility (due to a direct effect on the testes) but
with normal testosterone and gonadotrophin
levels. If additional radiation is given by a
testicular boost so that total doses are greater
than 20 Gy, testosterone levels may be low with
raised gonadotrophins and replacement therapy
may then be necessary.
Studies in pre - pubertal children suggest that
many boys and some girls receiving T81 may
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progress normally through puberty. Young age
at the time of treatment may be relatively
protective. Most boys will probably be
azoospermic, but patients who progress through
puberty with normal gonadotrophin and sex
hormone levels may be fertile (Sarafoglou et aI.,
1997; Sanders, 1997).
Although the probability of fertility cannot yet
be accurately predicted, pregnancies have been
reported after T81 given to males and females.
No abnormalities in offspring of these patients
have been reported, although the rate of
spontaneous abortion may be increased
(Sanders et aI., 1996).
D THYROID FUNCTION
The most common abnormality seen after
8MT with T81 conditioning is compensated or
over thypothyroidism with elevated TSH levels
with or without low free serum thyroxine or tri-
iode thyronine levels. Thyroid abnormalities,
which are commonly first detected between 12
and 60 months after treatment, have been
reported in 2 - 56% of patients treated with T81,
but hypothyroidism may also occur in up to 10%
of patients conditioned without T81 (Toubert et
aI., 1997). Replacement therapy is given early to
try to reduce the risk of induction of thyroid
malignancy.
o GROWTH
Growth may be affected by T81 in two ways.
1. By damage to the hypothalamus
and pituitary gland leading to
impaired growth hormone (GH)
production.
2. 8y a direct effect on the epiphyseal
plate leading to early epiphyseal
fusion.
Studies comparing effects of T81 with thoraco-
abdominal irradiation have shown that the
central effect is the most significant. Cranial
irradiation given before T81 increases the risk of
failure of GH production (Huma et aI., 1995).
Normal levels of GH may be maintained after
T81, especially if this is fractionated, or a pattern
of normal plasma levels with low GH peaks after
stimulation may be seen. Growth hormone
should be administered if GH levels are
measured to be low, if there is a low GH peak
after 2 stimulation tests and a loss of height
SDS of 1 SD or more (shown by measurement
of sitting rather than standing height). Low GH
peaks have been reported in 20 - 70% of
patients and graft versus host disease and poor
nutritional status increase the risk of GH failure.
Administration of growth hormone at an early
stage as soon as growth velocity starts to fall off
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prevents further decrease in height, although
"catch - up" growth does not occur.
Appropriate sex hormone administration is
also essential to obtain the full growth potential
of the pubertal growth spurt.
C HEART
Cardiac toxicity is not a major problem after
total body irradiation, although it has been
observed after high dose cyclophosphamide
therapy. Myocardial fibrosis and constrictive
pericarditis are late effects occurring many
years after conventional radiotherapy, and
careful follow-up of patients receiving total body
irradiation is necessary to determine whether
these same complications will develop. In one
study of 28 patients with leukaemia, serial echo
cardiography and radionuclide ventriculography
showed abnormalities in only 4, in whom the
resting ejection fraction was reduced after
treatment. Animal studies have shown acute
changes in the pattern of isoenzymes in mice
after total body irradiation and these enzyme
changes may lead to functional alterations. On
the basis of experience from conventional
radiotherapy it seems possible that coronary
artery disease or myocardial infarction may
occur at an earlier -age than normal in this
patient population (Kupari et aI., 1990).
B SECOND TUMOUR INDUCTION
In the first year or two after bone marrow
transplantation, the commonest malignancies
seen are recurrence of the original disease or
lymphoproliferative disorders which seem to be
related to immune suppression and Epstein Barr
virus infection (Darrington et aI., 1994).
A large study from the Seattle Group and the
International Bone Marrow Transplant Registry
has followed nearly 20,000 patients treated with
bone marrow transplantation to determine the
risk of developing a new solid cancer. 9,501
patients survived longer than 1 year and 73% of
the patients had TBI as part of the initial
conditioning for BMT. 3,200 patients have
survived for 5 years or more and in this group
80 second tumours were diagnosed. These
included 17 carcinomas of the buccal cavity or
pharynx, 11 brain tumours, 11 melanomas, 8
thyroid carcinomas, 9 bone and connective
tissue and 3 liver tumours. The overall risk of
developing a second tumour was inversely
related to the age at the time of bone marrow
transplant and directly related to time since
treatment, original tumour type and dose of
radiation (Curtis et aI., 1997).
Risk in children treated before the age of 10
was increased 36.6 times and at age 20 - 29
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4.6 times, whereas over the age of 39 the risk
was nearly the same as in a normal population.
Cumulative incidence was 0.7% at 5 years,
2.2% at 10 years and 6.7% at 15 years. Patients
with ALL were most likely to develop brain
tumours whereas melanoma occurred more
often in those treated for AML. Patients treated
with thoraco-abdominal or total body irradiation
had a higher risk than those conditioned without
radiation. No difference was seen whether TBI
was given as a single fraction or in several
fractions. The risk of brain tumours was highest
in those who had received cranial as well as
total body irradiation (9 of the 13 patients with
brain tumours).
Other factors which are possibly associated
with increased risk may be determined by
immunological abnormalities: T cell depletion
possibly related to melanoma induction, immune
abnormalities with oral mucositis and chronic
graft versus host disease for buccal cavity
tumours, cyclosporin administration (for skin
tumours), papilloma virus infection in squamous
cell carcinomas of skin and buccal mucosa.
Buccal cavity tumours are commonest in men.
The three parotid tumours observed were muco-
epidermoid carcinomas - the type also
observed in survivors of the atomic bomb.
It is interesting to compare this pattern of
second tumour incidence with that seen after
treatment of leukaemia without bone marrow
transplant when the cumulative incidence of
second tumours at 20 years is 2.9 - 4%. A
similar pattern of brain, thyroid, skin and
connective tissue tumours occurs, but the
greatest risk (27 times expected) is of brain
tumours in those treated with cranial irradiation
(Nygaard et aI., 1991).
These data underline the risk of radiation and
the need for prolonged follow-up. Patients
should be encouraged to avoid exposure to
known carcinogens (such as tobacco) which
may potentiate the effects of radiation.
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